Role of Magnesium Sulphate in Kidney and Coronary Artery Disease | ||||
| Zagazig University Medical Journal | ||||
| Volume 31, Issue 1, January 2025, Page 84-94 PDF (890.65 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2024.316951.3548 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Elshaimaa Ali Mohamed Elsadek 1; Mohamad Wafaei Abou-Eleinin2; Mohamed El-Hosanie Omar  3; Ismail Mohamed Ibrahim 4
| ||||
| 1Assistant Professor of Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| 2Professor of Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| 3Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| 4Lecturer of Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: The body uses magnesium for a wide range of physiological processes in both health and illness. Magnesium has an impact on energy production, electrolyte balance, and oxygen uptake in relation to muscle function. Magnesium needs are higher when participating in sports, especially during intense workouts when sweating a lot increases magnesium requirements. Reduced serum magnesium levels are linked to hypertension, Type 2 diabetes mellitus (T2DM), and metabolic syndrome; a lower chance of having the metabolic syndrome is associated with higher blood magnesium levels. Therefore, some people find that taking magnesium supplements is beneficial. It also seems that consuming more magnesium lowers the risk of high blood pressure. However, research on the use of magnesium with and without reperfusion therapy for coronary artery disease has shown contradictory findings. The question of whether magnesium should be administered as a first-line treatment was the subject of a protracted debate. Conclusion: In patients with myocardial infarction, intravenous magnesium cannot currently be suggested because the results of the most recent trials have not demonstrated any difference in outcome. Nonetheless, magnesium is indicated in torsade de pointes patients and has been effectively administered to patients with life-threatening ventricular arrhythmias or digoxin-induced arrhythmias. | ||||
| Keywords | ||||
| Magnesium sulphate; coronary artery disease; Kidney | ||||
|
Statistics Article View: 7,413 PDF Download: 97 |
||||
